Bintrafusp Alfa for Recurrent or Metastatic Cervical Cancer After Platinum Failure: A Nonrandomized Controlled Trial.

ABSTRACT:

Importance

Cervical cancer is a common and lethal cancer worldwide. Bintrafusp alfa is a first-in-class bifunctional fusion protein composed of the extracellular domain of the human transforming growth factor β receptor II (or transforming growth factor β trap) fused via a flexible linker to the C-terminus of each heavy chain of an immunoglobulin G1 antibody blocking programmed cell death 1 ligand 1.

Objective

To evaluate the safety and response rates of bintrafusp alfa in patients with recurrent or metastatic cervical cancer.

Design, setting, and participants

This phase 2 nonrandomized controlled trial evaluated bintrafusp alfa monotherapy in patients with recurrent or metastatic cervical cancer with disease progression during or after platinum-based chemotherapy. Da

SUBMITTER: Birrer M 

PROVIDER: S-EPMC11273284 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature